InvestorsHub Logo
Followers 20
Posts 2617
Boards Moderated 0
Alias Born 01/27/2022

Re: iwanderer post# 383725

Tuesday, 07/19/2022 12:14:18 PM

Tuesday, July 19, 2022 12:14:18 PM

Post# of 426450

Birdbrain I think you are asking WAY TOO MUCH for a penny stock CEO. He is NOT BP CEO.



^This, exactly.

And I've said this before. Amarin missed it's progression window. Small Bio startups are not Pfizer or Novartis or Merck.

Small bios start with guys that leave big pharma with some skills and knowledge. But usually they are science guys, not business guys. They hire business guys that have experience with bringing small bios public. Then they start their research, run trials, and then when they get to around Phase 3 and are looking at success, they try to get bought. And they have guys that know how to manage that process.

Obviously not EVERY biotech follows this pattern, but it's pretty typical. Most small bios are NOT staffed with the experience, skills, and depth to GIA in perpetuity. And this is why Amarin has been floundering since 2019. They missed their window to get bought, and now they are under-powered to GIA. So they have been forced to re-shape the company to operate on their own. And it's just not working. Too many important aspects of running the business have slipped through the cracks.

And this is why I sometimes defend the current team. Because they are a biotech startup team, forced to operate as if they are trying to build a big pharma organization.

KM has no experience running a pharma company. He has successfully built and managed sales organizations within big pharma. He was probably the right guy to run Europe. And maybe that's what he's still doing. And maybe the BOD is running the company. I don't know. But there's a definite mismatch between the skills and experience they NEED, and the skills and experience they HAVE.

I also think Amarin fucked up when they promoted JT. I can only assume they did that because they thought it would be a short-term (and cheap) answer to the CEO job for a company that was going to get bought shortly. He was the right guy for CFO. But not CEO. Then they lost the patents and it was game over for their hopeful buyout, and they were stuck with JT.

There's a pattern here.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News